Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Simmons AR, Baggerly K, Bast RC Jr.

Oncology (Williston Park). 2013 Jun;27(6):548-56. Review.

PMID:
23909069
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
[PubMed - indexed for MEDLINE]
3.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

PMID:
22028406
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.

Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D; Australian Ovarian Cancer Study Group, Obermair A.

Gynecol Oncol. 2013 Jun;129(3):467-71. doi: 10.1016/j.ygyno.2013.03.001. Epub 2013 Mar 13.

PMID:
23500084
[PubMed - indexed for MEDLINE]
5.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
[PubMed - indexed for MEDLINE]
6.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
[PubMed - indexed for MEDLINE]
7.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

PMID:
20593939
[PubMed - indexed for MEDLINE]
Free Article
8.

HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.

Chen WT, Gao X, Han XD, Zheng H, Guo L, Lu RQ.

Asian Pac J Cancer Prev. 2014;15(1):101-5.

PMID:
24528007
[PubMed - indexed for MEDLINE]
Free Article
9.

Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R.

Tumour Biol. 2012 Dec;33(6):2117-23. doi: 10.1007/s13277-012-0471-7. Epub 2012 Aug 9.

PMID:
22875782
[PubMed - indexed for MEDLINE]
10.

Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.

Paek J, Lee SH, Yim GW, Lee M, Kim YJ, Nam EJ, Kim SW, Kim YT.

Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):338-42. doi: 10.1016/j.ejogrb.2011.05.021. Epub 2011 Jun 17.

PMID:
21683503
[PubMed - indexed for MEDLINE]
11.

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.

BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

PMID:
22712526
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.

Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.

Gynecol Oncol. 2013 Feb;128(2):239-44. doi: 10.1016/j.ygyno.2012.09.034. Epub 2012 Oct 10.

PMID:
23063998
[PubMed - indexed for MEDLINE]
13.

The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.

Steffensen KD, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A.

Int J Gynecol Cancer. 2012 Nov;22(9):1474-82. doi: 10.1097/IGC.0b013e3182681cfd.

PMID:
23095772
[PubMed - indexed for MEDLINE]
14.

HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases.

Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J.

Tumour Biol. 2011 Dec;32(6):1087-95. doi: 10.1007/s13277-011-0204-3. Epub 2011 Aug 24.

PMID:
21863264
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Ovarian tumor markers of presumed benign ovarian tumors].

Lahlou N, Brun JL.

J Gynecol Obstet Biol Reprod (Paris). 2013 Dec;42(8):752-9. doi: 10.1016/j.jgyn.2013.09.030. Epub 2013 Nov 7. Review. French.

PMID:
24210243
[PubMed - indexed for MEDLINE]
Free Article
16.

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP.

Clinics (Sao Paulo). 2012;67(5):437-41.

PMID:
22666786
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

PMID:
23891789
[PubMed - indexed for MEDLINE]
Free Article
18.

HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P.

Eur J Gynaecol Oncol. 2011;32(6):605-10. Review.

PMID:
22335019
[PubMed - indexed for MEDLINE]
19.

A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.

Stiekema A, Lok CA, Kenter GG, van Driel WJ, Vincent AD, Korse CM.

Gynecol Oncol. 2014 Mar;132(3):573-7. doi: 10.1016/j.ygyno.2014.01.005. Epub 2014 Jan 10.

PMID:
24418200
[PubMed - indexed for MEDLINE]
20.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.

Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.

PMID:
23343214
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk